# METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin

> **NCT05504252** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University Hospital, Akershus** · enrollment: 80 (estimated)

## Conditions studied

- Colorectal Adenocarcinoma
- Mucinous Adenocarcinoma
- Signet Ring Cell Adenocarcinoma

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT05504252
- **Lead sponsor:** University Hospital, Akershus
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-10-05
- **Primary completion:** 2028-01-31
- **Final completion:** 2028-03-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-01-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05504252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05504252, "METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05504252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*